good news!

With the improvement of people's living standards, the pursuit of health has become higher and higher
.
Data shows that from the perspective of the composition of total health expenditures, personal health expenditures have accounted for less than 30% of total health expenditures in recent years.
The price reduction is closely related
.
In terms of the centralized procurement policy, the current centralized procurement has reached the sixth round.
In the previous rounds of centralized procurement of chemical drugs, the selected varieties have basically fallen by more than 50%; medical insurance negotiations are held once a year, and a large number of rare disease drugs, Oncology drugs are also included in the catalog through price reduction negotiations.
.
.
Under the implementation of these policies, the gospel to patients is obvious, which will greatly reduce the burden of patients' drug costs and improve the quality of life
.
The good news is that starting from 2022, another batch of drugs is expected to usher in a substantial decline
.
Among them, the new version of the National Medical Insurance Drug List will be officially launched nationwide from January 1
.
After this adjustment, a total of 74 new drugs have entered the catalog, including 20 drugs for chronic diseases such as hypertension, diabetes, hyperlipidemia, and psychosis, 18 drugs for oncology, 15 anti-infective drugs for hepatitis C and AIDS, and 7 drugs for rare diseases.
There are 2 kinds of drugs for the treatment of new coronary pneumonia, and 12 kinds of drugs for other fields
.
Compared with the original market price, through negotiation of price reduction and medical insurance reimbursement, this negotiation is expected to reduce the burden of patients by more than 30 billion yuan in 2022
.
Which new drugs have higher price cuts in the new "Catalog"? It’s not “Nosinagen Sodium Injection”.
This precision targeted therapy for the treatment of rare spinal muscular atrophy was originally nearly 700,000 injections, which is a level where many patients’ families need to sell their homes to afford the treatment costs.

.
Today, after negotiating a price cut, the price per injection has dropped to more than 30,000 yuan.
Excluding the medical insurance reimbursement part, the self-paid price is even lower
.
Based on 6 injections a year, the patient spends less than 200,000 yuan, and the burden of drug costs has been significantly reduced
.
The price of oncology drugs that have attracted much attention from patients has also been significantly reduced.
It is reported that the average price reduction of oncology drugs newly negotiated is 64.
88%, which exceeds the average price reduction of newly negotiated drugs in 2021.

.
Among them, the original research drug "daratumomab injection" for adult patients with multiple myeloma (MM) is also included in the medical insurance catalog this time.
The annual cost of the product was as high as one million yuan.
After Hunan, Liaoning Province and other places passed price cuts in 2021, the drop will be about 50%
.
Entering the medical insurance catalog this time, the price is expected to be further reduced
.
In addition, China’s self-developed PD-1 monoclonal antibody “Baizean” has added three new indications for medical insurance this time, including unresectable local late and advanced lung squamous cell carcinoma first-line, unresectable local late and late-stage drive Gene wild-type non-squamous cell carcinoma first-line, hepatocellular carcinoma that has undergone at least one systemic treatment
.
At present, the product has five indications that have been included in medical insurance
.
It is reported that the new price before the reimbursement of Baizeran medical insurance is adjusted to 1,450 yuan/piece (100mg), the price has dropped by 33.
49%, and the annual treatment cost is less than 50,000 yuan
.
Based on the 80% reimbursement ratio of medical insurance (subject to the actual reimbursement ratio of each region), the patient's self-paid annual treatment cost is only less than 10,000 yuan
.
It will once again improve the availability of medicines for patients and reduce the burden of relevant patients' medicines
.
In addition, after the implementation of the new "Catalog", patients with chronic diseases such as hypertension and diabetes are also expected to benefit
.
China is a big country with diabetes.
Currently, there are approximately 140 million diabetic patients.
Most of the patients need to take hypoglycemic drugs for life, which is accumulated over time, which is not a small burden for some patients' families
.
Take the newly approved diabetes drug smeglutide injection in 2021 as an example.
This drug only needs to be injected once a week, but it costs 1120 yuan each
.
Today, the drug has also entered the catalog through medical insurance negotiations.
The price of each drug has been reduced by more than half, at only 478 yuan.
After reimbursement by medical insurance, it is estimated that the patient will spend less than 1,000 yuan a month, which is significantly lower than before
.